Results 1 to 10 of about 22 (17)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series. [PDF]

J Med Case Rep, 2022
BACKGROUND: Giant cell arteritis is a large vessel vasculitis of the arteries in the head and neck. The mainstay of management is with high-dose corticosteroids, and patients often face difficulties stopping or reducing steroids without recurrence of ...
Saha P, Srikantharajah D, Kaul A, Sofat N.   +3 more
europepmc   +3 more sources

Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. [PDF]

Mol Cell Biol, 2002
p63 is a transcription factor structurally related to the p53 tumor suppressor. The C-terminal region differs from p53's in that it contains a sterile alpha motif (SAM) domain and is subject to multiple alternative splicings.
Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L.   +5 more
europepmc   +5 more sources

Life after tocilizumab given for giant cell arteritis: a patient survey and argument for re-treatment. [PDF]

Rheumatol Adv Pract
Quick V, Benson F, Mackie SL.
europepmc   +3 more sources

Benchmarking tocilizumab use for giant cell arteritis. [PDF]

Rheumatol Adv Pract, 2022
Conway R, Putman MS, Mackie SL.
europepmc   +1 more source

Relapse after cessation of weekly tocilizumab for giant cell arteritis:a multicentre service evaluation in England [PDF]

, 2023
OBJECTIVES: The National Health Service in England funds 12 months of weekly subcutaneous tocilizumab (qwTCZ) for patients with relapsing or refractory giant cell arteritis (GCA). During the COVID-19 pandemic, some patients were allowed longer treatment.

core   +3 more sources

Giant cell arteritis:reviewing the advancing diagnostics and management [PDF]

, 2023
Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss.
Bilton, Edward J., Mollan, Susan P.
core   +1 more source

Support available for and perceived priorities of people with polymyalgia rheumatica and giant cell arteritis: results of the PMRGCAuk members' survey 2017 [PDF]

, 2018
Polymyalgia rheumatica and giant cell arteritis are relatively common, but under research inflammatory rheumatological conditions. This survey aimed to ascertain the matters in which patients feel they need support with these conditions and appraise how ...
Busby, K, Gilbert, K, Hay, CA, Helliwell, T, Mallen, CD, Muller, SN, O'Brien, A, PMRGCAuk   +7 more
core   +2 more sources

Cave shrimps Troglocaris s. str. (Dormitzer, 1853), taxonomic revision and description of new taxa after phylogenetic and morphometric studies [PDF]

, 2012
FIGURE 1. Distribution map of eight taxa of the subgenus Troglocaris s. str., with phylogroup/subgroup designation (in brackets, as in Zakšek et al. 2009).
Jalžić, Branko, Jugovic, Jure, Prevorčnik, Simona, Sket, Boris   +3 more
core   +2 more sources

Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective [PDF]

, 2021
Giant cell arteritis, a common primary systemic vasculitis affecting older people, presents acutely as a medical emergency and requires rapid specialist assessment and treatment to prevent irreversible vision loss.
Brouwer, E, Conway, R, Mackie, SL, Mehta, P, Mollan, SP, Neill, L, Putman, M, Robinson, PC, Sattui, SE, van der Geest, KSM   +9 more
core  

Aqueous synthetic methods and their applications in DNA-encoded chemical libraries [PDF]

, 2019
Water is the basis for all living organisms on Earth and most biochemical processes proceed in aqueous environments. To study biological systems, chemists have developed numerous procedures to perform chemical transformations in the presence of water ...
Stress, Cedric
core   +1 more source